Alligator Bioscience
Monday, February 26, 2024
Uris
Non-Profit/Patient Advocacy Group
Alligator Bioscience is a clinical-stage biotech company developing agonistic antibody-based pharmaceuticals for tumour-directed immunotherapy of cancer.
Our lead asset, mitazalimab, a second generation CD40 agonist, is in phase 2 clinical development in first line pancreatic cancer in combination with chemotherapy. Interim data show promising efficacy and safety profiles. Mitazalimab has orphan designation with FDA and EMA. Top-line phase 2 data are expected early Q1 2024.
In addition, we are developing bispecific CD40xTAA agonists based on our proprietary Neo-X-prime™ concept and proprietary bsAb format, RUBY™. The first drug candidate, ATOR-4066, targeting CD40xCEA has recently entered IND-enabling studies.
State
Skane
Country
Sweden
Website
https://alligatorbioscience.se/en/
CEO/Top Company Official
Søren Bregenholt
Lead Product in Development
mitazalimab
Development Phase of Primary Product
Phase II
Number Of Unlicensed Products
3
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}